Showing results (441-450 of 645) with videos related to

Sort By:
Pageof 65
Contemporary Clinical Trials Communications|January 21, 2020
Audience segmentation as a strategy for enhancing the use of research registries for recruiting patients into clinical trialsElizabeth Flood-Grady, Jiawei Liu, Samantha R Paige, et al.
Arthritis and Rheumatism|August 29, 2009
Magnetic resonance imaging-based cartilage loss in painful contralateral knees with and without radiographic joint space narrowing: Data from the Osteoarthritis InitiativeFelix Eckstein, Olivier Benichou, Wolfgang Wirth, et al.
Critical Care Medicine|January 11, 2005
Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trialPierre-Francois Laterre, Howard Levy, Gilles Clermont, et al.
Cancer Immunology, Immunotherapy : CII|December 11, 2012
Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinomaRoniel Cabrera, Miguel Ararat, Yiling Xu, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium|March 1, 2019
Computable Eligibility Criteria through Ontology-driven Data Access: A Case Study of Hepatitis C Virus TrialsHansi Zhang, Zhe He, Xing He, et al.
BMC Genomics|November 20, 2010
Identification and developmental expression of the full complement of Cytochrome P450 genes in ZebrafishJared V Goldstone, Andrew G McArthur, Akira Kubota, et al.
Critical Care (London, England)|June 20, 2006
Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcomeAndrew F Shorr, Gordon R Bernard, Jean-Francois Dhainaut, et al.
Oncology Letters|December 4, 2012
Serum levels of soluble CD25 as a marker for hepatocellular carcinomaRoniel Cabrera, Asem I Fitian, Miguel Ararat, et al.
Hepatology (Baltimore, Md.)|March 3, 2010
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirinMoises Diago, Mitchell L Shiffman, Jean-Pierre Bronowicki, et al.
Clinical and Experimental Rheumatology|January 9, 2013
The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-α antagonist therapiesKhaled Sarsour, Jeffrey Greenberg, Joseph A Johnston, et al.
Pageof 65